The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 12, 2011, Pages 2827-2830

  Malet, Isabelle ^a   Fourati, Slim ^a   Charpentier, Charlotte ^b   Morand Joubert, Laurence ^a   Armenia, Daniele ^c   Wirden, Marc ^a   Sayon, Sophie ^a   Van houtte, Margriet ^d   Ceccherini Silberstein, Francesca ^c   Brun Vézinet, Françoise ^b   Perno, Carlo Federico ^c   Descamps, Diane ^b   Capt, André ^d   Calvez, Vincent ^a   Marcelin, Anne Geneviève ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d BVBA   (Belgium)

Author keywords

Integrase inhibitors; MK 2048; Phenotype

Indexed keywords

ABACAVIR; DARUNAVIR; DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; LAMIVUDINE; MK 2048; RALTEGRAVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; NONHUMAN; PHENOTYPE; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; VIRUS LOAD; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; MUTATION, MISSENSE; PYRROLIDINONES; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 81855199761     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr389     Document Type: Article

References (10)

1. Sato A, Kobayashi M, Yoshinaga T et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor. In: Abstracts of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Abstract WEPEA097.
2. Bar-Magen T, Sloan RD, Donahue DA et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010; 84: 9210-6.
3. Descamps D, Chaix ML, Montes B et al. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother 2010; 65: 2620-7.
4. Maiga AI, Malet I, Soulie C et al. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antivir Ther 2009; 14: 123-9.
5. Malet I, Delelis O, Valantin MA et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52: 1351-8.
6. Van Baelen K, Van Eygen V, Rondelez E et al. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 2008; 22: 1877-80.
7. Malet I, Soulie C, Tchertanov L et al. Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J Med Virol 2008; 80: 754-61.
8. Kobayashi M, Nakahara K, Seki T et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res 2008; 80: 213-22.
9. Geretti AM, Fearnhill E, Ceccherini-Silberstein F et al. Prevalence and patterns of raltegravir resistance in treated patients in Europe. In: Abstracts of the International HIV and Hepatitis Drug Resistance Workshop, Dubrovnik, Croatia, 2010. Abstract 51.
10. Ceccherini-Silberstein F, Malet I, D'Arrigo R et al. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009; 11: 17-29.